APA

Branford S., Rudzki Z., Harper A., Grigg A., Taylor K., Durrant S., Arthur C., Browett P., Schwarer A. P., Ma D., Seymour J. F., Bradstock K., Joske D., Lynch K., Gathmann I. & Hughes T. P. (20040123). Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. : Leukemia.

Chicago

Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, Arthur C, Browett P, Schwarer A P, Ma D, Seymour J F, Bradstock K, Joske D, Lynch K, Gathmann I and Hughes T P. 20040123. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. : Leukemia.

Harvard

Branford S., Rudzki Z., Harper A., Grigg A., Taylor K., Durrant S., Arthur C., Browett P., Schwarer A. P., Ma D., Seymour J. F., Bradstock K., Joske D., Lynch K., Gathmann I. and Hughes T. P. (20040123). Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. : Leukemia.

MLA

Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, Arthur C, Browett P, Schwarer A P, Ma D, Seymour J F, Bradstock K, Joske D, Lynch K, Gathmann I and Hughes T P. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. : Leukemia. 20040123.